Morpholine

Morpholine

SCHEMBL21145317

C1COCCN1.CCC(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
CYP2C9 P11712 1/20 0.50
FFAR3 O14843 2/20 0.48
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.35
GLA P06280 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
TSHR P16473 2/20 0.32
GABRA5 P31644 3/20 0.31
GABRB2 P47870 3/20 0.31
GABRA1 P14867 2/20 0.31
GABRA4 P48169 2/20 0.31
GABRP O00591 1/20 0.31
GABRD O14764 1/20 0.31
GABRB1 P18505 1/20 0.31
GABRG2 P18507 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Morpholine SCHEMBL22500932 0.98 MEN1 (0.48) KMT2AMEN1KDM4EGAACYP2C9
Oxazolidine SCHEMBL4299921 0.86 FFAR3 (0.43) KMT2AMEN1KDM4EGAACYP2C9
Morpholine SCHEMBL28036779 0.86 KMT2A (0.50) KMT2AMEN1KDM4EGAACYP2C9
Morpholine SCHEMBL11191668 0.85 FFAR3 (0.54) KMT2AMEN1KDM4EGAACYP2C9
Propionic Acid SCHEMBL3790146 0.84
Morpholine SCHEMBL22501136 0.84 KDM4E (0.48) KMT2AMEN1KDM4EGAACYP2C9
Succinic Acid SCHEMBL3330322 0.83 KDM4E (0.52) KMT2AMEN1KDM4EGAACYP2C9
Morpholine SCHEMBL9162514 0.83 MEN1 (0.52) KMT2AMEN1KDM4EGAACYP2C9
Morpholine SCHEMBL29207396 0.82 KMT2A (0.58) KMT2AMEN1KDM4EGAACYP2C9
Morpholine SCHEMBL219044 0.82 KMT2A (0.58) KMT2AMEN1KDM4EGAACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113786711-A Method for recovering chlorine-containing volatile organic compounds in organic waste gas by using ionic liquid 郑州中科新兴产业技术研究院 2021-12-14 CN claimed
CN-104662004-B Novel rebamipide prodrug, method for producing same, and usage thereof 三进制药株式会社 2017-04-19 CN claimed
US-20250242275-A1 APPARATUS AND METHOD FOR PROCESSING A BIOMASS MATERIAL BUSS-SMS-CANZLER GMBH (DE) 2025-07-31 US disclosed
US-20250145889-A1 METHOD FOR PROCESSING A BIOMASS MATERIAL PROIONIC GMBH (AT) 2025-05-08 US disclosed
US-12291502-B2 Topoisomerase II-alpha inhibitors and methods of treating cancer using the same THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2025-05-06 US disclosed
EP-4377467-A2 METHOD FOR PROCESSING A BIOMASS MATERIAL proionic GmbH (AT) 2024-06-05 EP disclosed
CN-113474388-B Method for converting phenyl isocyanate 陶氏环球技术有限责任公司 2024-03-22 CN disclosed
WO-2023084131-A2 METHOD FOR PROCESSING A BIOMASS MATERIAL PROIONIC GMBH (AT) 2023-05-19 WO disclosed
US-20230105776-A1 Topoisomerase II-alpha Inhibitors and Methods of Treating Cancer Using the Same UNITED STATES GOVERNMENT 2023-04-06 US disclosed
CN-110621766-B Dispersant, method of manufacture and use thereof 雪佛龙奥伦耐有限责任公司 2021-12-24 CN disclosed
CN-113786711-A Method for recovering chlorine-containing volatile organic compounds in organic waste gas by using ionic liquid 郑州中科新兴产业技术研究院 2021-12-14 CN disclosed
CN-110621766-A Dispersant, method of manufacture and use thereof 雪佛龙奥伦耐有限责任公司 2019-12-27 CN disclosed
US-20190240129-A1 CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION HENKEL AG & CO. KGAA (DE) 2019-08-08 US disclosed
EP-3518878-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION Henkel AG & Co. KGaA (DE) 2019-08-07 EP disclosed
US-20190216703-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION HENKEL AG & CO. KGAA (DE) 2019-07-18 US disclosed
US-20190216714-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION HENKEL AG & CO. KGAA (DE) 2019-07-18 US disclosed
CN-109071483-A Penicilones derivative and its application as drug-resistance bacteria medicine 扬州蓝色生物医药科技有限公司 2018-12-21 CN disclosed
CN-104662004-B Novel rebamipide prodrug, method for producing same, and usage thereof 三进制药株式会社 2017-04-19 CN disclosed
CN-106132972-A For treating the novel amino phosphate ester of HCV infection 银杏树药业(苏州)有限公司 2016-11-16 CN disclosed
CN-1711239-A Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RES & DEV (FR) 2005-12-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230105776-A1 Topoisomerase II-alpha Inhibitors and Methods of Treating Cancer Using the Same TOP2A, TOP1, TOP2B KMT2A 1122/4885MEN1 2288/4885KDM4E 2961/4885
US-20190240129-A1 CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION KRT18, CUTA, S100A10 KMT2A 242/4885MEN1 3369/4885KDM4E 461/4885
US-12291502-B2 Topoisomerase II-alpha inhibitors and methods of treating cancer using the same TOP2A, TOP1, TOP2B KMT2A 1122/4885MEN1 2288/4885KDM4E 2961/4885
US-20190216703-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION KRT18, SRRM2, IK KMT2A 912/4885MEN1 4505/4885KDM4E 1699/4885
US-20190216714-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION KRT18, CD44, PCNA KMT2A 97/4885MEN1 2001/4885KDM4E 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.